Kezhen L. Tang

Statistics

Publications

Citations

6.9K

H-Index

Active since

1988

Affiliations

Janssen (United States)(Current)

Icahn School of Medicine at Mount Sinai

Evangelismos Hospital

Janssen Scientific Affairs (United States)

University of California San Diego

Kezhen L. Tang is an author at Janssen (United States) specializing in pharmacotherapy, inflammatory bowel disease, and inflammatory bowel disease therapy.

Publications per year

1988–2018

Publications

Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease

Jean‐Frédéric Colombel, William J. Sandborn, Walter Reinisch et al. · New England Journal of Medicine · 2010 · 3.1K citations · Full text

Pharmacy, Immunology, Pharmacotherapy +14

Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease

Ajay Singh, Lynda A. Szczech, Kezhen L. Tang et al. · New England Journal of Medicine · 2006 · 2.8K citations · Full text

Medicine, Hematology, Pharmacotherapy +10

Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial

Freddy Cornillie, Stephen B. Hanauer, Robert H. Diamond et al. · Gut · 2014 · 373 citations · Full text

Veterinary Medicine, Immunology, Pharmacotherapy +17

Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel Disease

Jeffrey S. Hyams, Marla C. Dubinsky, Robert N. Baldassano et al. · Gastroenterology · 2017 · 216 citations

Medicine, Immunology, Pediatrics +15

Validation of Endoscopic Activity Scores in Patients With Crohn's Disease Based on a Post Hoc Analysis of Data From SONIC

Marc Ferrante, Jean‐Frédéric Colombel, William J. Sandborn et al. · Gastroenterology · 2013 · 178 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +10

1–5 of 12